Cencora Deepens Its Oncology Footprint With American Oncology Network Deal
Cencora’s agreement to buy American Oncology Network for an enterprise value of $2.4 billion pushes the drug distributor further into physician practice management at a moment when oncology is increasingly shaped by scale, distribution control, and outpatient care consolidation. The transaction is structured to give Cencora a much larger stake in a physician-led network that already fits neatly inside its broader strategy: build ownership around community-based cancer care without taking clinical decision-making away from physicians.
The deal assigns $2.3 billion at closing, with up to $100 million in contingent value rights tied to future conditions. Cencora already owns about 4% of AON. If eligible stockholders roll over up to 25% of their equity, Cencora expects to spend about $1.7 billion to reach 75% ownership. AON’s board approved the transaction after a special committee of independent directors unanimously recommended it.
The structure is as important as the headline price. A controlling stake in a physician network allows a distributor to move closer to the point where oncology care, pharmacy access, and practice operations intersect. In community oncology, that can mean tighter coordination of infusion services, specialty drug distribution, and practice support functions that smaller groups often struggle to manage alone. The clinical model remains physician-led, but the business backbone becomes more centralized and more durable.
A Physician-Led Network Built for Community Oncology
Founded in 2018, AON has grown into a management services organization with more than 350 oncology providers across 21 states. It supports independent practices with practice management, technology, and ancillary services. Under the transaction, AON will join Cencora’s MSO platform and add 12 states to that footprint.
AON physicians retain control of clinical decisions.
That detail matters in oncology because treatment selection, sequencing, and supportive care decisions depend on close physician judgment even when the back-office model changes. Community practices often sit at the center of cancer care for patients who need frequent visits, complex drug regimens, and long-term follow-up close to home. A network like AON can preserve that local access while supplying the infrastructure needed to negotiate reimbursement pressure, manage prior authorization burdens, and keep infusion and specialty services running at scale.
Cencora has already been investing in AON since 2020 and serves as its distribution partner. The relationship suggests this transaction is less of a sudden turn than a continuation of a strategy already in motion. For a company built around pharmaceutical distribution, physician network ownership offers a way to align logistics with care delivery in one of medicine’s highest-cost, highest-complexity specialties.
Thin Trading and Private Ownership Pressures Shaped AON’s Path
AON’s public-company chapter was brief. It went public in 2023 through a merger with a special purpose acquisition company, then voluntarily delisted from Nasdaq in June 2024. Thin trading, limited analyst coverage, and the cost of public reporting drove that decision. The company now trades on the OTCQX.
At the time of delisting, AON had more than 240 providers. Since then, the network has expanded materially, and the deal with Cencora values that growth in a way public markets had not fully captured. For physician groups, the tension is familiar: public listing can offer capital and visibility, but it can also impose reporting burdens that do not always match the operational realities of a care-delivery enterprise. Private capital, and now majority ownership by a distributor, can offer speed and stability, though it also concentrates strategic control.
The broader implication for oncology is straightforward. Consolidation is moving deeper into the physician segment, and the assets drawing the most interest are not hospitals but the outpatient practices that deliver chemotherapy, monitor toxicity, and manage cancer as a chronic, episodic disease. In that setting, the network itself becomes part of the treatment ecosystem.
Smaller Practices, Larger Practices, and a Two-Track Oncology Strategy
Investment experts view AON as a complementary fit with OneOncology, which focuses on larger practices. Cencora agreed in December 2025 to take majority control of OneOncology in a $5 billion deal. The AON transaction extends that same playbook into a different slice of the market: smaller providers and community-based practices that may need a different mix of operational support.
This split is clinically relevant because oncology does not operate as a single uniform market. Large practices and smaller practices face different pressures, different payer dynamics, and different thresholds for technology investment. A network that can support both ends of that spectrum gains leverage in the outpatient cancer economy. It can spread administrative infrastructure, scale purchasing relationships, and create a larger channel for specialty oncology therapies that are often expensive, protocol-driven, and operationally demanding.
AON’s role in that structure is not to replace the physician practice. It is to reinforce it with the kind of management layer that can help practices survive in a market increasingly defined by margin pressure and complex drug distribution.
A Wider Wave of Distributor Consolidation in Specialty Care
Cencora is not moving alone. Cardinal Health agreed in September 2024 to acquire Integrated Oncology Network for $1.12 billion and also bought a majority stake in GI Alliance for $2.8 billion. McKesson paid $2.49 billion for a controlling interest in Core Ventures, the MSO for Florida Cancer Specialists & Research Institute. Cencora itself agreed in March to buy EyeSouth Partners’ retina business for $1.1 billion, following its $4.4 billion acquisition of an 85% stake in Retina Consultants of America, completed in January 2025.
The pattern is hard to miss. Drug distributors are no longer content to remain at arm’s length from the practices that use their products. They are buying into the physician groups, the MSOs, and the specialty care channels that determine where drugs are administered and how closely patients can be held within a coordinated system. In oncology, where treatment depends on access to high-cost therapeutics, infusion infrastructure, and rapid handling of side effects, control over the delivery platform can be as strategically valuable as control over the product line.
Cencora’s leadership framed the move in terms of expanding a physician-led oncology MSO and supporting care in communities across the country. AON’s leadership emphasized that Cencora understood the mission because it has been both an investor and an oncology industry partner for years. The transaction now waits on the mechanics of closing and the degree to which eligible stockholders choose to roll over equity. What remains unresolved is less about strategic direction than about how much of community oncology will ultimately sit inside distributor-owned networks rather than alongside them.